GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (STU:KK3A) » Definitions » Float Percentage Of Total Shares Outstanding

Cytokinetics (STU:KK3A) Float Percentage Of Total Shares Outstanding : 76.46% (As of May. 17, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cytokinetics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cytokinetics's float shares is 91.31 Mil. Cytokinetics's total shares outstanding is 119.43 Mil. Cytokinetics's float percentage of total shares outstanding is 76.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cytokinetics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cytokinetics's Institutional Ownership is 78.85%.

Cytokinetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cytokinetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=91.31/119.43
=76.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (STU:KK3A) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
KRYS IONS AXSM ADMA NUVL PCVX BPMC RYTM PTCT SRPT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CYTK:USA KK3A:Germany
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.cytokinetics.com
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics Headlines

No Headlines